➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Express Scripts
Harvard Business School
Mallinckrodt

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Fluzoparib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Fluzoparib?

Fluzoparib is an investigational drug.

There have been 24 clinical trials for Fluzoparib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2020.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Breast Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd., and Beijing Cancer Hospital.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for Fluzoparib
TitleSponsorPhase
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer PatientsJiangsu HengRui Medicine Co., Ltd.Phase 2
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell CarcinomaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPhase 2
A Study of Fluzoparib in Combination With FOLFIRINOX in Patients With Resectable Pancreatic CancerJiangsu HengRui Medicine Co., Ltd.Phase 1

See all Fluzoparib clinical trials

Clinical Trial Summary for Fluzoparib

Top disease conditions for Fluzoparib
Top clinical trial sponsors for Fluzoparib

See all Fluzoparib clinical trials

US Patents for Fluzoparib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fluzoparib   Start Trial Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)   Start Trial
Fluzoparib   Start Trial Methods of using phthalazinone ketone derivatives Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fluzoparib

Drugname Country Document Number Estimated Expiration Related US Patent
Fluzoparib Australia 2011288876 2030-08-09   Start Trial
Fluzoparib Brazil 112013002220 2030-08-09   Start Trial
Fluzoparib Canada 2806324 2030-08-09   Start Trial
Fluzoparib China 102372716 2030-08-09   Start Trial
Fluzoparib China 102686591 2030-08-09   Start Trial
Fluzoparib European Patent Office 2604610 2030-08-09   Start Trial
Fluzoparib Spain 2582315 2030-08-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Medtronic
Express Scripts
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.